Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
North Carolina Voter Guide 2024: Who's running, how, where, when to vote in NC election
Recommended
Find a flu shot
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Atsena Therapeutics
Atsena Therapeutics to Present ATSN-201 Safety and Efficacy Data at the American Academy of Ophthalmology 2024 Annual Meeting
October 10, 2024
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 24, 2024
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
September 17, 2024
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of ATSN-101 in LCA1 Published in The Lancet
September 05, 2024
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
August 14, 2024
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Appoints Joseph S. Zakrzewski as Board Chair
July 15, 2024
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
May 01, 2024
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
March 13, 2024
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
January 16, 2024
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
December 04, 2023
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
November 14, 2023
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisis
August 28, 2023
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis
May 01, 2023
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
April 25, 2023
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Announces Six-Month Data from Phase I/II Clinical Trial of ATSN-101 to be Presented at ARVO 2023 Annual Meeting
April 11, 2023
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1) at the 46th Annual Macula Society Meeting
February 08, 2023
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics to Present at NewYorkBIO’s December 2022 Emerging Life Science Company Showcase
December 07, 2022
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer
November 07, 2022
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)
October 03, 2022
From
Atsena Therapeutics
Via
GlobeNewswire
Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle
July 27, 2022
From
Atsena Therapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.